5 Minutes Read

Serum Institute wants to advance needle-free injection tech so picked 20% in this US-based company

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

SII CEO Adar Poonawalla said the company envisions a needle-free solution to deliver vaccines and the US-patented technology will be available in the Indian private market.

Serum Institute of India (SII) has picked a 20% state in a little-known US-based company IntegriMedical as the company envisions a needle-free solution to deliver vaccines. Financial details were not disclosed.

SII CEO Adar Poonawalla said, “At SII, we are constantly seeking opportunities to invest in technologies that align with our mission to make healthcare accessible and affordable for people worldwide.”

Speaking about IntegriMedical’s US-patented Needle-Free Injection System (N-FIS), Poonawalla said it represents a significant advancement in drug delivery and could revolutionise the way vaccines are administered, making the process more comfortable for patients and healthcare professionals.

What is known about IntegriMedical

IntegriMedical is a privately owned medical technology company focused on providing innovative drug delivery solutions for patients suffering from needle phobia.

The company’s says it has research centres and manufacturing facilities in the US, India, and Hong Kong.

What is known about the needle-free technology

IntegriMedical has developed a US-patented needle-free injection system (N-FIS) that utilises a high-velocity jet stream using mechanical power to administer biologics and drugs.

According to the company, N-FIS has received regulatory approvals from CDSCO, CE, and MDSAP and is ISO 13485 certified.

The investment by Serum is expected to accelerate the development and commercialisation of the N-FIS technology, making it more widely accessible to patients in India and worldwide, the companies said in a release.

 

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Aarti Pharmalabs shares rally over 12% after March quarter net profit increases 52%

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Aarti Pharmalabs Share Price | The company’s board has also recommended a final dividend of ₹1 per equity share of ₹5 each (20%) to the members for the financial year ended March 31, 2024.

Aarti Pharmalabs shares gained nearly 12% on Tuesday, May 14, after the company reported over a 52% growth in net profit for the March quarter. The company also announced a dividend payout for eligible shareholders after market hours on Monday.

The pharmaceutical company’s shares rallied over 12% to hit an intra-day high of ₹591.60 per share. It was trading 12.68% higher at ₹586 apiece at 12.05 pm.

The company reported a 52.2% jump in its consolidated net profit at ₹65.25 crore for the fourth quarter of the financial year 2023-24 from the previous year’s ₹42.87 crore. The net profit was also 23% more than the previous quarter’s ₹52.76 crore.

The company’s net profit for FY24 increased by 12.09% to ₹216.9 crore from ₹193.49 crore in FY23.

Aarti Pharmalabs’ total income increased by 4.5% to ₹507.8 crore, compared to the previous year’s ₹485.8 crore. The company also witnessed a nearly 13% jump in its total income from the December quarter’s ₹450.08 crore.

The pharmaceutical company’s total income for FY24 declined by 4.62% to ₹1,857.5 crore against ₹1,947.55 crores in FY23.

The board has recommended a final dividend of ₹1 per equity share of ₹5 each (20%) to the members for the financial year ended March 31, 2024. The dividend recommended by the board is subject to the approval of the shareholders at the ensuing annual general meeting of the company.

Around 10:23 am, shares of Aarti Pharmalabs were trading 8.96% higher at ₹566.8 apiece on the BSE.

Also Read: From Dixon Technologies to Tips Industries: FIIs increased their stake in these five companies

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Healthcare consulting firm ZS unveils data science’s role in personalised treatments and streamlined trials

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Manish Menon of ZS discusses the transformative impact of data science in healthcare. He highlights its role in personalized treatments, streamlined clinical trials, and predicts breakthroughs in AI and analytics, emphasizing the potential for enhancing patient engagement and cybersecurity.

In today’s healthcare arena, data science is the guiding light, paving the way for personalised treatments and streamlined clinical trials. In a conversation with CNBC-TV18, Manish Menon, office managing principal for management consulting and technology firm ZS, unveils the profound impact of data analytics, offering insights into its transformative role in patient care.

“Data science helps enable the early identification of individuals at high risk for specific conditions such as cancer or heart disease by sifting through data sources like Electronic Medical Records (EMR), Electronic Health Records (EHR), Electronic Patient Records (EPR), transactional and biometric data, genetic information, etc. and analysing it for diagnoses, biomarker discovery and disease subtyping,” Menon said.

Elaborating on the process, Menon outlined key steps, including defining the right data strategy, data management, hypothesis creation, and constant learning from additional datasets. These steps, he highlighted, are essential for harnessing the full potential of data science in healthcare.

Discussing the unravelling of genetic variability and the identification of molecular biomarkers in disease progression, Menon highlighted the integration of genes and the environment.

“We have sophisticated AI/ML models centred on disease ontologies and patient journeys to predict critical events such as metastasis in oncology patients, forecast treatment line progression, and anticipate specific debilitating milestones within disease journeys,” he added.

On the subject of streamlining clinical trials through data analytics, Menon mentioned the significant challenges faced in patient enrollment and operational inefficiencies. He discussed how AI and analytics hold promise in optimising trial processes, citing examples such as GenAI’s accelerated delivery efficiency in identifying potential treatments.

Menon also detailed ZS’s contributions to supporting clinical research and optimising trials through acquisitions like Trials.ai and Intelligencia.ai.

Furthermore, Menon shed light on ZS’s AI-powered solutions that effectively understand patient needs and enhance engagement. He mentioned Max.AI’s generative AI capabilities as groundbreaking innovations, alongside ZAIDYN, an intelligent platform streamlining sales performance management.

Looking towards the future, Menon anticipates breakthroughs in AI, ML, and analytics. He emphasised GenAI’s potential to enhance patient engagement and treatment adherence, along with advancements in natural language processing (NLP) and multimodality. Additionally, he highlighted the role of AI in cybersecurity, underscoring its ability to predict and respond to cyber threats swiftly.

Also Read: Why aligning traditional practice and new medical knowledge is important for newborn health

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Horlicks drops ‘health’ label, changes to ‘functional nutritional drink’; know the difference

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The Ministry of Commerce and Industry earlier asked all e-commerce platforms to remove drinks and beverages from the ‘healthy drinks’ category.

Hindustan Unilever (HUL), the owner of Horlicks and Boost, has rebranded its ‘health food drinks’ category to ‘functional nutritional drinks’ (FND), following the recent regulatory changes in the health drinks category.

This comes after the Ministry of Commerce and Industry ordered all e-commerce platforms to remove drinks and beverages from the ‘healthy drinks’ category.

“NCPCR, a statutory body constituted under section (3) of the Commission for Protection of Child Rights (CPCR) Act, 2005 after its inquiry under Section 14 of CPCR Act, 2005, concluded that there is no Health Drink defined under FSS Act 2006, Rules and regulations as submitted by FSSAl and Mondelez India Food Pvt Ltd,” read the notification issued by the ministry on April 10.

Further, it stated that “all e-commerce companies/portals are hereby advised to remove drink/beverages, including Bournvita from the category of ‘health drinks’ from their sites/platforms.”

On April 24, Ritesh Tiwari, the chief financial officer of Hindustan Unilever, said, “We have changed the labels of the category to FND which is a much better way to call it.”

Tiwari noted the FND category is under-penetrated, so there is a big opportunity for growth in the same. He added that the company would focus on increasing customers and usage and giving more benefits to them to upgrade in the FND category.

Difference between health drinks and functional nutritional drinks

For years in India, malt-based beverages have been popularly referred to as health drinks. These products enhance the taste of milk, besides offering some nutritional benefits.

On April 2, the Food Safety and Standards Authority of India (FSSAI) asked e-commerce Food Business Operators (FBOs) to ensure appropriate categorisation of the food products which are sold on their respective websites. The move came after it noted instances of dairy-based beverage mixes, cereal-based beverage mixes or malt-based beverages, which are licensed under ‘Proprietary Food’, being sold on e-commerce websites under categories like ‘Health Drink’, ‘Energy Drink’ and others.

It clarified that the term ‘Health Drink’ is not defined or standardised anywhere under the FSS Act 2006 or in the rules/regulations made thereunder.

According to FSSAI, the term ‘Energy’ drinks is permitted to be used only for products that are licensed under Food Category System (FCS) 14.1.4.1 and 14.1.4.2 (Carbonated and Non-carbonated water-based flavoured drinks), standardised under sub-regulation 2.10.6 (2) of Food Product Standards and Food Additives Regulations 2011 (Caffeinated Beverage).

Proprietary Foods are food items not standardised under various FSSAI regulations but use standardised ingredients.

The reason behind the decision was to “enhance clarity and transparency regarding the nature and functional properties of the products,” the statement said.

FSSAI wants to ensure that consumers can make well-informed choices while buying a product without encountering misleading information.

This comes amid ongoing debates regarding the sugar levels in popular malt-based beverages being sold in the country.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Why aligning traditional practice and new medical knowledge is important for newborn health

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

When discussing traditional practices for newborns, Dr. Verma highlights the rich history of ancient medicine. However, he stresses the need for aligning these traditional practices with modern medical knowledge.

In a world where medical advancements are rapidly transforming healthcare, it’s crucial to balance traditional practices with modern interventions, especially when it comes to the health of newborns says Dr. Rahul Verma, Head, Neonatology Department, and Director, Paediatrics Sciences, at Sir H. N. Reliance Foundation Hospital and Research Centre. 

Key Problems Faced by Newborns Today

 Dr. Verma emphasises that one of the most prevalent issues affecting newborns is the incidence of premature births. However, he notes a positive trend —the increasing survival rate of premature infants, thanks to advancements in neonatal care.

Additionally, low birth weights and babies classified as small for gestational age are frequently observed, affecting both urban and rural populations.

 Navigating Traditional Practices

When discussing traditional practices for newborns, Dr. Verma highlights the rich history of ancient medicine. He acknowledges the efficacy of practices like oil massage but emphasises the importance of understanding their purpose and execution.

According to him, the gentle touch stimulation provided by oil massages is beneficial for babies, but the manner in which it’s done matters greatly. Dr. Verma suggests that family members should perform the massage gently, using oil solely as a lubricant. However, he cautions against using oils that may be harmful to the baby’s delicate skin and stresses the significance of hygiene and cleanliness during the massage process.

 Rediscovering Traditional Medicine

Delving deeper into traditional practices, Dr. Verma urges awareness of their origins and purposes. For instance, he explains that the traditional practice of tying black threads around a baby’s ankles was intended to monitor growth. However, he notes the need for alignment between various such traditional practices and modern medical knowledge.

As Dr. Verma concludes, striking a balance between tradition and modernity is essential for ensuring the optimal health and well-being of newborns. By understanding the roots and rationale behind traditional practices and integrating them with evidence-based medical interventions, we can provide comprehensive care for the newest members of our society.

 

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

myCGHS iOS app launched for Central Government Health Scheme beneficiaries

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Users on the Apple ecosystem can find the app on the App Store and download it free of cost. It provides online appointment booking, access to medical records, lab reports, claim status, referrals, wellness centers, news updates, and nearby healthcare facilities.

The Union Health Ministry launched the myCGHS app for iOS on Wednesday to provide easy access for the Central Government Health Scheme (CGHS) beneficiaries to their Electronic Health Records, information, and other resources.

“The myCGHS iOS app is developed by the technical teams of the National Informatics Centre (NIC) Himachal Pradesh and NIC Health Team. It is a convenient mobile application offering features aimed at enhancing information and accessibility for CGHS beneficiaries,” the ministry said in a press release.

The app is said to offer a range of services, including online appointment booking and cancellation, downloading CGHS card and index card, accessing lab reports from CGHS labs, checking medicine history, monitoring medical reimbursement claim status, accessing referral details, locating nearby wellness centres, staying updated with news and highlights, and finding nearby empanelled hospitals, labs, and dental units.

Additionally, users can access the contact details of wellness centres and offices conveniently. To ensure data security, the app also features security measures such as two-factor authentication and mPIN function to be able to access the app once they are logged in.

Users on the Apple ecosystem can find the app on the App Store and download it free of charge. The ministry has not mentioned which version of iOS will support the app, so it is suggested to keep your Apple device updated.

The myCGHS app has been available for Android users since February 2022 and has over a lakh downloads on the Google Play Store, according to data available on the platform.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Indian-origin teen first to get UK’s life-changing cancer treatment

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

According to NHS England, 16-year-old Thakkar from Watford near London was the first child in the UK to benefit from a pioneering CAR T therapy called tisagenlecleucel (Kymriah) thanks to its Cancer Drugs Fund (CDF).

Yuvan Thakkar, an Indian-origin teenager diagnosed with cancer, says he is now able to enjoy the things he loves after life-changing treatment thanks to a fund set up by the UK’s state-funded National Health Service to make innovative therapies accessible to thousands of patients.

According to NHS England, 16-year-old Thakkar from Watford near London was the first child in the UK to benefit from a pioneering CAR T therapy called tisagenlecleucel (Kymriah) thanks to its Cancer Drugs Fund (CDF).

It comes as the National Health Service (NHS) marks a milestone this weekend of 100,000 patients benefitting from early access to the latest and most innovative treatments with the help of CDF.

The undisclosed cost of such treatments is covered by the fund.

My life has changed so much since I received the CAR T therapy, said Thakkar, who thanked Great Ormond Street Hospital (GOSH) in London for the incredible care he received.

I remember I had to take so many trips to hospital and had long periods out of school.

They have helped me recover to a state where I am able to enjoy so many things I love doing, such as playing snooker or pool, meeting friends and family, and going on wonderful holidays.

It’s hard to imagine how things would have been if the treatment wasn’t available, he said.

Thakkar, diagnosed with a form of leukaemia aged six, received a treatment which modifies a person’s immune cells to recognise and attack cancer cells.

His treatment began in 2019, when he was 11 years old after he relapsed following other treatments such as chemotherapy and a bone marrow transplant.

His mother Sapna said the family had received a second chance at life since the success of the treatment.

Without the fast-track access available through the CDF, the 45-year-old said there may have been no other way for her son to receive the life-saving treatment.

It felt like our prayers were finally answered. We still feel so grateful for this chance that’s been given to us and not a single day passes by when we haven’t felt thankful for all the doctors and nurses that have helped us through this long and difficult journey, said Sapna Thakkar.

The CDF, which opened in its current form in July 2016, is used by NHS England to provide fast-tracked access for patients to all new cancer treatments approved by the National Institute for Health and Care Excellence (NICE), in addition to gathering further evidence of long-term effectiveness for promising drugs.

It allows faster access to more than 100 drugs to help improve, extend or in some cases save their lives.

Treating 100,000 cancer patients in England with innovative treatments through the Cancer Drugs Fund is a fantastic milestone for the health service to reach, and testament to the hard work of oncologists and their teams across the country, said Professor Sir Stephen Powis, NHS national medical director.

This vital fund is helping ensure patients get access to the most promising drugs far quicker than would otherwise be the case, helping people with cancer like Yuvan receive a life-changing intervention that sets a path for a longer, healthier life spent with family and friends, he said.

The fund benefits people with common cancers, such as breast, lung, colorectal and prostate, as well as those with less common cancers, such as ovarian, cervical, kidney, skin, myeloma, lymphoma and leukaemia, and rare cancers, including thyroid and biliary tract.

The current CDF budget of GBP 340 million is 70% more than the previous CDF and is used alongside NHS England’s Innovative Medicines Fund of GBP 340 million, which the health service said means a total of GBP 680 million is ringfenced for fast-tracking new medicines.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Samantha Prabhu slammed for promoting herb for liver detox? What’s Ayurveda-Allopathy debate?

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

While dandelion has been traditionally used in various cultures for its supposed health benefits, including liver support, contemporary research offers ‘mixed results’. Researches have shown protective effects of dandelion. Hence, it’s factual that it works on liver, but most of these studies were conducted on animals. If it will work the same way on human bodies is still fictitious to an extent

Samantha Ruth Prabhu is facing backlash after a video surfaced online, which accused the actor of spreading misinformation about “liver detoxification” to her fans and 33.5 million followers on Instagram.

In a widely circulated clip from the podcast on Prabhu’s show, the guest talks about the benefits of herbs such as “dandelion” for liver health and detoxification. But is liver detoxification actually real or is it more like a myth than a medical reality?

Medical experts have criticised the concept of detoxification and asserted that the use of herbs can lead to irreversible damage to the liver.

Some doctors told News18 that the efficacy of the liver detox concept, particularly those promoted by alternative medicine or home remedies, should be studied carefully. While the idea of “detoxifying” the liver may seem appealing, it’s essential to understand the science behind it.

The liver is a powerhouse organ, naturally equipped to detoxify the body. It already possesses highly efficient mechanisms for detoxification. These include enzymatic processes that break down toxins and the excretion of waste products through bile and urine. Therefore, the notion of needing additional detoxification methods beyond what the liver naturally performs is not supported by scientific evidence.

Despite strong words of caution from the medical community, ayurvedic experts support the concept.

AYURVEDA VS MODERN MEDICINE

Doctors practising modern medicine or allopathy advised to apply caution.

According to Dr Sanjay Goja, programme director, liver transplant and robotic liver surgery, at Gurugram-based Narayana Hospital, the notion of needing additional detoxification methods beyond what the liver naturally performs is not supported by scientific evidence.

Some liver detox practices, Goja said, such as extreme fasting or consuming large quantities of specific juices or supplements, can be counterproductive and potentially harmful.

“I have encountered several cases where patients have experienced adverse effects from attempting liver detox regimens. For instance, one patient developed severe liver inflammation after following a strict juice cleanse for an extended period. Another individual experienced liver toxicity from excessive consumption of herbal supplements purported to cleanse the liver.”

Also Read: Why collaboration in healthcare will remain a cornerstone of progress

He further said certain home remedies or practices rooted in Ayurveda – despite being traditional – can pose risks to liver health if used improperly or in excess.

“For example, the indiscriminate use of certain herbs or herbal concoctions without medical supervision can lead to liver toxicity or drug interactions,” he cautioned.

On the contrary, ayurveda experts swear by the concept. They say the concept of liver detoxification helps for healthy as well as unhealthy liver.

For instance: Anurag Varshney, head, drug discovery and development research at Patanjali Research Institute, Haridwar, explained to News18 the other side of the story.

“There are multiple published research suggesting that the extracts of dandelion, either leaves or roots, have good potential to take care of liver ailments… This work has been done by several research laboratories across the globe and has been published in peer-reviewed scientific journals. These herbs can be used even to keep the liver healthy,” Varshney said.

Contrary to many medical experts, Varshney thanked Samantha Prabhu for bringing forth the power of herbal medicines and open endorsement of the natural way of staying healthy.

WHAT DO STUDIES SAY ABOUT DANDELION?

While dandelion has been traditionally used in various cultures for its supposed health benefits, including liver support, contemporary research offers “mixed results”, several studies shared by Ayurveda experts showed the protective effects of dandelion.

Research published in The Journal of Basic and Applied Zoology in July 2020 showed that dandelion prevents the progression of “hepatic fibrosis”. “The dandelion’s anti-fibrotic effects could be attributed to its ability to scavenge free radicals and to attenuate inflammatory cell activations,” said the study. It was, however, conducted on adult male albino rats and not humans.

Similarly, another study published in Food and Chemicals Toxicology in 2013 showed that dandelion leaf extracts (DLE) significantly suppressed lipid accumulation in the liver, and reduced insulin resistance. “These results indicate that the DLE may represent a promising approach for the prevention and treatment of obesity-related non-alcoholic fatty liver disease.” This study was again conducted on mice.

Also Read: Doctors must mention reason while prescribing anti-biotics, says Health Ministry

Another study published in the Journal of King Saud University in 2022 showed that dandelion seed extract treatment resulted in a marked decrease of liver enzyme activities in addition to hepatic tissue improvement. But this study again was conducted on Swiss albino mice.

Given emerging evidence on the liver protective effects of dandelion, the majority of ayurvedic studies have advised designing large human clinical studies.

Dr Sarathchandra Gorantla, consultant gastroenterologist, hepatologist (liver doctor) and advanced therapeutic endoscopist at Hyderabad-based Yashoda Hospitals said the concept of “detoxifying” the liver with specific herbs or supplements, including dandelion, is a popular notion.

“For instance, research has indicated that dandelion root extract might help prevent liver damage in rats with induced liver failure and may have antioxidant properties beneficial for liver health.”

“However, these findings cannot be directly extrapolated to humans without further clinical trials,” Gorantla said while adding that “as a responsible celebrity, it is essential to present well-researched, scientifically accurate information to the public. Hence, promoting unsubstantiated claims about liver detoxification through herbal remedies like dandelion could lead to misconceptions and potentially harmful self-treatment attempts.”

Johns Hopkins Medicine stresses that the liver does not require detoxification products for daily health maintenance. Many products claiming to detox the liver are not regulated even by the world’s top regulatory authorities such as the US Food and Drug Administration, lack uniformity, and have not been adequately tested in clinical trials.

CONCLUSION

Multiple studies shared by experts showed the protective effects of dandelion — hence, its factual that it works on liver, positively. But the majority of these studies are on animals. So, to say it will work the same way on human bodies is still fictitious, to an extent.

The liver is highly capable of detoxifying itself, and the best way to support liver health is through a healthy lifestyle. Therefore, the safest and most effective way to support liver function is through healthy lifestyle choices, nothing else.

Also Read: Puberty to Menopause: A comprehensive guide to women’s health

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Cancer-causing chemical detected in acne treatments from Clinique, Target and more – Reports

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Benzene was also detected in other acne treatment products, including Proactiv, PanOxyl, Walgreens’ acne soap bar, and Walmart’s Equate Beauty acne cream, among others, as reported by Reuters.

Independent US laboratory Valisure revealed alarming levels of the cancer-causing chemical benzene in select acne treatments, including those from brands such as Estee Lauder’s Clinique, Target’s Up & Up, and Reckitt Benckiser-owned Clearasil, according to a report by Reuters.

Valisure, based in New Haven, Connecticut, has petitioned the US Food and Drug Administration (FDA) to recall these products, conduct a thorough investigation, and revise industry guidelines.

Estee Lauder’s shares experienced a 2% decline following the disclosure. Benzene was also detected in other acne treatment products, including Proactiv, PanOxyl, Walgreens’ acne soap bar, and Walmart’s Equate Beauty acne cream, among others, as reported by Reuters.

Valisure cautioned that benzene levels could exceed acceptable limits in both prescription and over-the-counter benzoyl peroxide acne treatment products. Reckitt, Clearasil’s parent company, disputed the findings, stating they were based on unrealistic scenarios rather than real-world conditions.

Estee Lauder emphasised the safety of Clinique’s benzoyl peroxide product when used as directed.

Reuters reached out to Target and Walmart for comment but did not elicit a response, and the FDA has yet to respond to Valisure’s petition. The presence of benzene in acne treatment products presents a significant departure from previous instances where benzene was detected as an impurity in contaminated ingredients.

David Light, Co-Founder and President of Valisure, highlighted that in this case, benzene originates from the benzoyl peroxide itself.

Valisure’s tests indicated that some products could contain benzene levels exceeding the FDA’s concentration limit by more than 800 times.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Private hospitals in India fear ‘armageddon’ if costs are standardised

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

India’s top court has given the government a month to fix standard rates for different medical procedures. A failure to comply may result in the court considering the implementation of standardised rates as prescribed in the Central Government Health Scheme.

India’s top court, responding to a public interest litigation filed by an NGO, has given the government a month to fix standard rates for different medical procedures. Private healthcare heads now fear an ‘armageddon‘ if rates similar to Central Government Health Scheme (CGHS) are mandated to be applied to procedures in private hospitals.

Viren Shetty, Executive Vice Chairman at Narayana Health, said: “The difference between CGHS and private hospital rates can range from 20% to 60%. Applying CGHS rates to all services would be an ‘Armageddon’ for private healthcare.”

India’s Supreme Court has raised its concern over the wide variation in medical treatment costs between government and private healthcare facilities. It has asserted that citizens of India have a fundamental right to healthcare, and the centre cannot evade its responsibility in ensuring this right.

The court highlighted the stark contrast in prices, citing an example of cataract surgery, which costs around ₹10,000 in a government hospital but can range from ₹30,000 to ₹1,40,000 in a private facility. This is despite healthcare costs in India being considerably lower than in other parts of the world.

Underlining the industry caters to people across the spectrum, Shetty of Narayana Health said there was a need to evaluate rates amid rising healthcare costs.

Bino Pathiparampil from Elara Securities also feels all listed private hospitals are likely to be impacted if this mandate is followed. “Everything cannot be priced at the same level when it comes to healthcare,” Pathiparampil told CNBC-TV18.

Downside risks for private hospitals

Financial services company Macquarie has presented a cautionary perspective, suggesting that cash-paying patients in private hospitals currently bear a considerably higher financial burden compared to those covered by CGHS.

The CGHS rates are 40-50% lower for medical procedures, so Macquarie said the move could result in a substantial drop in profits for private healthcare providers.

Private hospitals, particularly those with lower Average Revenue Per Occupied Bed (ARPOBs) and a higher proportion of cash-paying patients, may face bigger challenges if CGHS rates are mandated.

The industry, as a whole, is closely monitoring the government’s response to these directives.

According to Axis Securities, the implementation of the Clinical Establishment Act 2010 (CEA) poses significant difficulties.

A plausible outcome could involve the Central Government proposing to the Supreme Court the formation of a committee comprising representatives from different state governments. However, building consensus among diverse stakeholders is anticipated to be a time-consuming process, possibly extending over several months if not years, the brokerage said.

This uncertainty is expected to cast a shadow over the hospital sector until clarity emerges.

Jefferies, in its analysis, said that the litigation surrounding the standardisation issue is still at an early stage.

Contrary to foreseeing any near-term adverse outcomes, the firm added that the price weakness in the sector gives a potential buying opportunity.

Jefferies highlighted that adverse news flows are not uncommon for the sector and have historically not always translated into tangible effects.

CLSA acknowledged the Supreme Court’s directive for standardising rates as a negative development for private hospitals, acknowledging the inherent difficulties in implementation.

Despite the challenges, CLSA retained an ‘outperform’ rating on Apollo Hospital, setting a target price of ₹7,000.

Government’s response and the way forward

The court has asked the central Government to set standard procedure rates within a month. A failure to comply may result in the court considering the implementation of standardised rates as prescribed in the CGHS.

The complexity of determining procedure rates, as suggested by the Clinical Establishment Rules 2012, requires collaboration between the Central government and state governments.

In the event of standardised rates being implemented, insurance companies are anticipated to align their reimbursement rates accordingly.

It remains to be seen how the government will address these concerns and whether a standardised approach to medical treatment costs will be implemented. The outcome could have far-reaching implications for both healthcare providers and the citizens of India seeking affordable and standardised healthcare services.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?